What is it about?
Presentation of some clinical outcomes reached by different mTOR and PI3K inhibitors.
Featured Image
Why is it important?
PI3K/mTOR signaling pathway is deregulated in cancers and inhibition of this cue may represent an attractive therapeutic option to treat cancer patients.
Read the Original
This page is a summary of: Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers, Recent Patents on Anti-Cancer Drug Discovery, August 2016, Bentham Science Publishers,
DOI: 10.2174/1574892811666160519113731.
You can read the full text:
Contributors
The following have contributed to this page
